医药生物行业周报：ADA大会临近，建议关注GLP-1产业链

Investment Rating - The report maintains a "Positive" investment rating for the pharmaceutical and biotechnology industry [2]. Core Insights - The upcoming ADA conference is highlighted as a significant event for the GLP-1 industry chain, with expectations of increased market activity and visibility for Chinese innovative drug companies [4][11]. - Recent strategic collaborations in the industry, such as between Hansoh Pharmaceutical and Regeneron, and BMS with BioNTech, indicate a robust investment environment and potential for growth in innovative drug development [11]. - The report emphasizes the importance of the GLP-1 sector, suggesting specific companies to watch, including Zai Lab, Boryung Pharmaceutical, and others involved in GLP-1 innovation and supply chain [11]. Summary by Sections 1. Industry Overview - The pharmaceutical and biotechnology sector reported a weekly return of 1.13%, ranking 17th among 31 primary sub-indices [9]. - Over the past month, the sector achieved a return of 6.48%, ranking 2nd among the same indices [9]. 2. Market Performance and Valuation - The current PE (TTM) for the pharmaceutical and biotechnology industry is 28.18 times, which is below the historical average of 31.15 times [17][20]. - The industry has shown a relative performance of 4.76% against the CSI 300 index over the past month, indicating strong market positioning [23]. 3. Market Tracking - The chemical pharmaceutical sub-sector has shown the highest weekly return of 1.67% and a monthly return of 10.92% [33]. - Notable individual stock performances include Yiming Pharmaceutical and Wanbangde, with significant weekly increases of 33.09% and 32.59%, respectively [35]. 4. Industry and Company Dynamics - Recent policy updates from the Guangdong Provincial Medical Insurance Bureau aim to enhance drug procurement processes, indicating a move towards a more standardized and competitive market [44]. - Key industry news includes the approval of a nine-valent HPV vaccine by Wantai Biological Pharmacy and ongoing clinical trials for chronic hepatitis B treatments [45].